ByHeart Updates Information Regarding Voluntary Recall of all Batches of ByHeart Whole Nutrition Infant Formula Cans and Packs Because of Possible Health Risk

ByHeart has voluntarily recalled all batches of its Whole Nutrition Infant Formula (24 oz cans and 0.6 oz Anywhere Pack™, UPCs 5004496800/5004496802) after independent testing identified Clostridium botulinum in some samples and amid an ongoing multistate infant botulism investigation; the company and U.S. regulators report 31 infants with suspected or confirmed illness and confirmed exposure to ByHeart formula across 15 states (illness onsets Aug. 9–Nov. 13, 2025), all hospitalized and no deaths reported to date. ByHeart says it is testing every batch with third‑party lab IEH, providing full access to FDA and state health authorities, advising consumers to stop use and preserve cans for potential testing, and is cooperating with CDC and state partners. The recall and confirmed bacterial findings create immediate public‑health, regulatory and reputational risk for ByHeart and could materially disrupt distribution, invite further investigation and potential liability as more test and case results are reported.

Analysis

ByHeart has initiated a voluntary recall of all batches of ByHeart Whole Nutrition Infant Formula (24 oz cans and 0.60 oz Anywhere Pack™, UPCs 5004496800 and 5004496802) after independent third‑party testing by IEH identified Clostridium botulinum in some samples. The recall follows an ongoing multistate outbreak investigation and the company states it is cooperating with FDA, CDC and state partners while warning consumers not to use product even if it appears normal.

Regulators and ByHeart report 31 infants with suspected or confirmed infant botulism and confirmed exposure to the formula across 15 states, with illness onset dates ranging from August 9 to November 13, 2025; all 31 infants were hospitalized and no deaths have been reported to date. Laboratory confirmation is ongoing for some cases, which keeps the epidemiologic and legal case count open and subject to change.

ByHeart says it is testing every batch with an independent lab, providing full access to facilities and cans for regulatory testing, and advising consumers to preserve containers for possible testing; Canadian authorities have issued a food safety warning and the product was distributed nationwide online and in retail. The combination of confirmed bacterial findings, a full‑product recall, and ongoing case confirmation creates immediate reputational, regulatory and potential liability risk, consistent with the strongly negative sentiment (-0.85) and a material market impact score (0.65). Investor outcomes will depend on the scope of contamination, ongoing test results and any subsequent civil or regulatory actions, all of which are unresolved.

Key Decisions for Investors

• Avoid initiating new long exposure to ByHeart or related consumer infant‑formula positions until regulatory testing and case confirmations materially narrow the contamination scope, monitor FDA/CDC and company testing updates closely
• Treat near‑term revenue disruption and reputational damage as likely; assume retail distribution and online channels will face interruptions and factor extended sales recovery and remediation costs into valuation models
• Watch for legal and regulatory triggers—additional confirmed cases, formal FDA enforcement actions, or class‑action filings—as those events should prompt reassessment or defensive positioning
• If exposed, consider hedging or reducing position sizes to limit tail liability risk and require updated disclosure on insurance coverage and estimated remediation costs before adding exposure